Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors.Ten distinct prostaglandin receptors on different cell types are currently known. G-protein-coupled receptors are a subclass of cell surface seven-transmembrane receptors that prostaglandins bind to. The following are the names of these receptors: FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor, EP1-4-EP1, EP2, EP3, and EP4 receptors. A class of lipid molecules known as prostaglandins, which are produced enzymatically from fatty acids and resemble hormones, play vital roles in the bodies of animals. Ten distinct prostaglandin receptors on different cell types are currently known.

Prostaglandin Receptor related products

Structure Cat No. Product Name CAS No. Product Description
V74491 I-SAP 133538-58-6 I-SAP is a radioactive TXA2/PGH2 receptor antagonist.
V8868 Iloprost (Ciloprost; ZK-36374) 78919-13-8 Iloprost (Ciloprost; ZK-36374; Trade names: Ventavis, Ilomedine), a novel potent synthetic analog of prostacyclin PGI2, is an approved drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and other diseases in which the blood vessels are constricted and blood can't flow to the tissues.
V74468 Iloprost-d4 (Iloprost d4) 1035094-10-0 Iloprost-d4 is the deuterium labelled form of Iloprost.
V74492 KMN-80 1628759-75-0 KMN-80, an analogue of PGE1, is a selective agonist of EP4 receptor, with IC50 and Ki of 3 nM and 2.35 nM respectively.
V4363 LAROPIPRANT 571170-77-9 Laropiprant (aslo known as MK-0524; Cordaptive) is a novel, potent, selective DP [prostaglandin D2 (PGD2) receptor (DP)] receptor antagonist with Ki values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.
V80538 Latanoprost-d4 (PHXA41-d4) Latanoprost-d4 is the deuterium labelled form of Latanoprost.
V5017 Misoprostol 59122-46-2 Misoprostol (formerly known as SC29333), a synthetic prostaglandin E1 (PGE1) analog, is a medication used to treat missed miscarriage, to induce labor, and to induce abortion.
V4292 MK-2894 1006036-87-8 MK-2894 is a novel, potent and selective antagonist of prostaglandin E2 subtype 4 receptor (PGE2).
V4293 MK-2894 sodium 1006036-88-9 MK-2894 sodium is a novel, potent and selective antagonist of prostaglandin E2 subtype 4 receptor (PGE2).
V4288 MK-447 58456-91-0 MK-447 (MK447) is a novel and potent free radical scavenger.
V4314 MK-7246 1218918-62-7 MK-7246 is a novel, potent and selective CRTH2 antagonist with Ki of 2.5±0.5 nM.
V74497 MK-7246 S enantiomer 2310135-53-4 MK-7246 S enantiomer is the less active enantiomer of MK-7246.
V5217 MRE-269 (ACT-333679) 475085-57-5 MRE-269 (also known as MRE269; ACT-333679), an active metabolite of selexipag (also known as NS-304), is a novel, potent along-acting and selective IP (prostaglandin I2) receptor agonist.
V74486 MRE-269-d7 (ACT-333679-d7) 1265295-20-2 MRE-269-d7 is the deuterium labelled form of MRE-269 .
V37610 NTP42 2055599-51-2 NTP42 is a novel thromboxane A2 (TXA2) receptor antagonist with an IC50 of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca2+] mobilization following stimulation of cells with the alternative TP agonist U46609.
V79159 NXT-10796 NXT-10796 is an orally bioactive entero-restricted EP4 receptor agonist (activator).
V76681 ONO-8711 dicyclohexylamine ONO-8711 dicyclohexylamine is a potent and specific competitive EP1 antagonist (inhibitor) with Kis of 0.6 nM and 1.7 nM for human and mouse EP1, respectively.
V74477 ONO-8713 459411-08-6 ONO-8713 is a selective prostaglandin E receptor subtype EP1 antagonist.
V4681 ONO-AE3-208 402473-54-5 ONO-AE3-208 is a novel and potent EP4 antagonist with Ki of 1.3 nM.
V21605 Ozagrel Sodium 189224-26-8 Ozagrel Sodium (formerly known as KCT-0809 and Cataclot) is the sodium salt of Ozagrel(also known as OKY-046) which is a potent and selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet, it is used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.
Contact Us Back to top